Guosheng Yuan
5PUBLICATIONS
3CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Mar 13, 2025
Low-Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma.Rong Li, Wenli Li, Qing Yang
|Dec 29, 2023
Spleen-dedicated stiffness measurement performed well to rule out high-risk varices in HBV-related hepatocellular carcinoma: Screening for high-risk varices in HCC.Xiao Cheng, Yujun Tang, Qinjun He
|Dec 17, 2020
Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.Guosheng Yuan, Xiao Cheng, Qi Li
|Jul 07, 2020
Withdrawn: Effectiveness and safety of toripalimab, camrelizumab and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients.Guosheng Yuan, Xiaoyun Hu, Qi Li
|May 17, 2017
A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study.Guosheng Yuan, Chengguang Hu, Yuchen Zhou
Pageof 1
